BIOCAD is developing a new drug for melanoma treatment
At this time BIOCAD is studying several molecules. The most successful candidate will become a new product in 2018-2019.
Candidate molecules are monoclonal antibodies to PD-1 antigen that stimulate patient immune system to destroy cancer cell. BIOCAD is planning to launch 1-2 new generation drugs every year starting in 2018.
Source: TASS